The main risk from the US’ new pharmaceutical tariff framework may not be immediate trade disruption, but a gradual diversion of global investment away from Singapore, according to CGS International. The announcement on 2 April to impose tariffs of up to 100% on selected biochemical (HS29) and pharmaceutical (HS30) products introduces fresh uncertainty for Singapore’s biomedical sector. CGS International views the near-term impact as contained, whilst highlighting a more structural risk from shifting multinational investment decisions that could weaken Singapore’s long-term positioning in high-value manufacturing. The proposed tariffs primarily target patented biomedical products, an area where Singapore has built significant specialisation. For HS29 products, patented active pharmaceutical ingredients (APIs) accounted for about $3.17b (US$2.5b) of Singapore’s exports to the US in 2024, compared with $348.52 (US$274m) for generics. In HS30 pharmaceuticals, patented products contributed around $1.52b (US$1.2b) versus just $0.89m (US$0.7m) for generics.   https://sbr.com.sg/in-focus/why-singapores-high-value-pharma-specialisation-now-primary-us-target (ICE SINGAPORE)

Fonte notizia: Singapore Business Review, 14 May 2026